|
Oct 9
|
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design
|
|
Aug 14
|
Windtree Announces New Additions and Changes to Its Board of Directors
|
|
Jul 25
|
Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data
|
|
Apr 8
|
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
|
|
Feb 1
|
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
|
|
Dec 19
|
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
|
|
Dec 18
|
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
|
|
Aug 23
|
Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office
|
|
Jun 27
|
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
|
|
Apr 27
|
Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime
|